These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35320555)

  • 1. Topical henna and curcumin (Alpha®) ointment efficacy for prevention of capecitabine induced hand-foot syndrome: A randomized, triple-blinded, placebo-controlled clinical.
    Elyasi S; Rasta S; Taghizadeh-Kermani A; Hosseini S
    Daru; 2022 Jun; 30(1):117-125. PubMed ID: 35320555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
    Elyasi S; Shojaee FSR; Allahyari A; Karimi G
    Phytother Res; 2017 Sep; 31(9):1323-1329. PubMed ID: 28635153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of topical
    Mohajerani R; Shahi F; Jafariazar Z; Afshar M
    Cutan Ocul Toxicol; 2021 Sep; 40(3):257-262. PubMed ID: 34152880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study.
    Scontre VA; Martins JC; de Melo Sette CV; Mutti H; Cubero D; Fonseca F; Del Giglio A
    J Diet Suppl; 2018 Sep; 15(5):606-612. PubMed ID: 29095653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
    Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
    J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
    Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
    JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
    Santhosh A; Sharma A; Bakhshi S; Kumar A; Sharma V; Malik PS; Pramanik R; Gogia A; Prasad CP; Sehgal T; Gund S; Dev A; Cheung WY; Pandey RM; Kumar S; Gupta I; Batra A;
    J Clin Oncol; 2024 May; 42(15):1821-1829. PubMed ID: 38412399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
    Santhosh A; Kumar A; Pramanik R; Gogia A; Prasad CP; Gupta I; Gupta N; Cheung WY; Pandey RM; Sharma A; Batra A
    Trials; 2022 May; 23(1):420. PubMed ID: 35590388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical henna for capecitabine induced hand-foot syndrome.
    Yucel I; Guzin G
    Invest New Drugs; 2008 Apr; 26(2):189-92. PubMed ID: 17885735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial.
    Andayani YD; Saleh MI; Sudoyo AW; Ali Z; Legiran L; Partan RU; Yuristo E; Lubis FZ
    Acta Med Indones; 2023 Oct; 55(4):396-402. PubMed ID: 38213043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials.
    Kao YS; Lo CH; Tu YK; Hung CH
    Dermatol Ther; 2022 Oct; 35(10):e15774. PubMed ID: 36054263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Single-Blinded Phase II Trial Comparing Efficacy and Quality of Life of Topical Aloe Vera Gel Plus Urea Cream Versus Urea Cream Alone for Prevention of Hand Foot Syndrome in Cancer Patients Receiving Capecitabine.
    Wanichtanom L; Vrakornvoravuti G; Boonsiri M; Suthepwanon A
    Asian Pac J Cancer Prev; 2024 Jun; 25(6):2203-2210. PubMed ID: 38918684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of EVOSKIN®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial.
    Lu W; Huang Z; Chen S; Lv H; Chen X; Lei J; Ke C; Hong C; Wei Y; Su R; Chen R; Sun Z; Yang P; Tan X; Liu H
    Ann Palliat Med; 2021 Mar; 10(3):3009-3017. PubMed ID: 33849091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised controlled feasibility trial to evaluate Lawsonia inermis (henna)'s effect on palmar-plantar erythrodysesthesia induced by capecitabine or pegylated liposomal doxorubicin.
    Stavrinou M; Tsitsi T; Astras G; Paikousis L; Charalambous A
    Eur J Oncol Nurs; 2021 Apr; 51():101908. PubMed ID: 33626423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).
    Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Miura K; Oshio H; Ohori H; Ariyoshi K; Oyamada S; Iwase S
    Support Care Cancer; 2020 Aug; 28(8):3649-3657. PubMed ID: 31811480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study).
    Iimura Y; Furukawa N; Ishibashi M; Ahiko Y; Tanabe T; Aikou S; Shida D; Nojima M; Kuroda S; Boku N
    BMC Gastroenterol; 2022 Jul; 22(1):341. PubMed ID: 35836104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a Novel Soaking Solution Used in Patients With Hand-Foot Syndrome as a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial.
    Xie Y; Wang Q; Hu T; Chen R; Wang J; Chang H; Peng X; Cheng J
    Clin Breast Cancer; 2022 Jul; 22(5):e685-e690. PubMed ID: 35354530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
    Huang XZ; Chen Y; Chen WJ; Zhang X; Wu CC; Wang ZN; Wu J
    Int J Cancer; 2018 Jun; 142(12):2567-2577. PubMed ID: 29355976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical henna ameliorated capecitabine-induced hand-foot syndrome.
    Ilyas S; Wasif K; Saif MW
    Cutan Ocul Toxicol; 2014 Sep; 33(3):253-5. PubMed ID: 24021017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
    Lou Y; Wang Q; Zheng J; Hu H; Liu L; Hong D; Zeng S
    Chem Res Toxicol; 2016 Oct; 29(10):1591-1601. PubMed ID: 27631426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.